Results 241 to 250 of about 66,881 (311)

Effectiveness of interventions to increase healthcare workers' adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022. [PDF]

Euro Surveill
Clari M, Albanesi B, Comoretto RI, Conti A, Renzi E, Luciani M, Ausili D, Massimi A, Dimonte V.   +8 more
europepmc   +1 more source

Waning of Humoral Immunity to Vaccine-Preventable Diseases in Children Treated for Acute Lymphoblastic Leukemia: A Single-Center Retrospective Cross-Sectional Analysis [PDF]

Turk J Haematol
İnce T, Tüfekçi Gürocak Ö, Totur G, Yılmaz Ş, Ören H, Aydın A.   +5 more
europepmc   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, EarlyView.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Prioritizing Feasible and Impactful Actions to Enable Secure AI Development and Use in Biology

Biotechnology and Bioengineering, EarlyView.
ABSTRACT As artificial intelligence continues to enhance biological innovation, the potential for misuse must be addressed to fully unlock the potential societal benefits. While significant work has been done to evaluate general‐purpose AI and specialized biological design tools (BDTs) for biothreat creation risks, actionable steps to mitigate the risk
Josh Dettman, Emily Lathrop, Aurelia Attal‐Juncqua, Matthew Nicotra, Allison Berke   +4 more
wiley   +1 more source

RBD‐SD1 Nanoparticle Vaccines From DPP4‐Using Merbecoviruses Elicit a Cross‐Reactive Antibody Response but Limited Cross‐Protective Immunity

Biotechnology and Bioengineering, EarlyView.
SpyCatcher‐mi3 nanoparticles displaying RBD‐SD1 from MERS‐CoV, NL140422, and HKU4 elicited robust and cross‐reactive IgG responses in mice. Only MERS‐CoV RBD‐SD1 induced neutralizing antibodies against MERS‐CoV and protected human DPP4 mice from a MERS‐CoV challenge, indicating conserved serologic but limited cross‐neutralizing epitopes.
Peter J. Halfmann, Jeong Soo Lee, Tong Wang, Augustine Duffy, Janie E. Rogers, Natasha Chen, Elizabeth Frimpong, Carmen Rai, Yoshihiro Kawaoka, Ravi S. Kane   +9 more
wiley   +1 more source

Putting an End to an Unconstitutional Result: Equal Protection and Due Process Analyses of the Requirement that Female Immigrants Receive the Gardasil Vaccine Prior to Becoming Permanent Residents of the United States [PDF]

, 2009
Sheyn, Elizabeth R.
core   +2 more sources